研究进展 Wed, 18 Ma

Cognition Therapeutics reports Zervimesine slows NPI decline in DLB

来源: Longevity Technology

Cognition Therapeutics presented an analysis from the Phase 2 COG1201 SHIMMER study of Zervimesine (CT1812) in dementia with Lewy bodies at the AD/PD 2026 conference in Copenhagen, held March 17-21

原文链接

阅读原文 →